This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Ethics declarations
Competing interests
As a result of the financings completed by Symphony Capital Partners and its affiliates listed in Table 1, Mark Kessel and Sam Hall have certain economic interests in the biotech companies listed therein and the respective collaborative partnering companies developing those indications.
Rights and permissions
About this article
Cite this article
Kessel, M., Hall, S. Avoiding premature licensing. Nat Rev Drug Discov 5, 985–986 (2006). https://doi.org/10.1038/nrd2203
Issue Date:
DOI: https://doi.org/10.1038/nrd2203
This article is cited by
-
Erratum: Avoiding premature licensing
Nature Reviews Drug Discovery (2007)